HC Wainwright Rates AgomAb Therapeutics (AGMB) buy
HC Wainwright maintains a buy rating for AgomAb Therapeutics NV with a $35 price target, a 176.03% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated AgomAb Therapeutics NV ($AGMB) "buy" with a $35 price target on June 22, 2026.
Since the rating, $AGMB is up 50.5% after 1 week, down 2.0% after 1 month and down 30.1% to date (from the $11.84 close on Jun 22, 2026).
AGMB
AgomAb Therapeutics NV
Key Points
- HC Wainwright reiterated its buy rating for AgomAb Therapeutics NV (AGMB) with a $35 price target on June 22, 2026.
- HC Wainwright's $35 price target implies 176.03% upside from AgomAb Therapeutics NV's ($AGMB) current $12.68 share price.
- Shares of AgomAb Therapeutics traded near $10.98 on Tuesday, with a market cap of about $583 million and a 52-week range from $8.75 to $17.45.
- TCG Crossover Management opened a new position in AgomAb Therapeutics, acquiring over 2 million shares valued at approximately $21.5 million.
Get $AGMB trade alerts by text
We text you when insiders, Congress or big funds trade $AGMB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AgomAb Therapeutics NV alert may contain errors. Disclosures
On June 22, 2026, HC Wainwright reiterated its buy rating for AgomAb Therapeutics NV (NasdaqGS: AGMB) with a price target of $35. The analyst behind this rating is Patrick R. Trucchio, who continues to see potential in the company's future performance.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in AgomAb Therapeutics
TCG Crossover Management, LLC opened a new position in AgomAb Therapeutics, acquiring 2,053,233 shares. This new stake is valued at approximately $21.5 million, signaling a significant interest in the company's prospects.
AgomAb Therapeutics NV Stock Up 4.2%
Shares of NasdaqGS:AGMB traded near $10.98 on Tuesday. AgomAb Therapeutics has a market cap of about $583 million. The stock has traded between $8.75 and $17.45 over the past 52 weeks. It has a 50-day moving average of $10.98 and a 200-day moving average of $12.25. The company maintains a strong liquidity position with a current ratio of 6.52 and a quick ratio of 6.49, but it is not currently profitable, showing a forward P/E ratio that is not meaningful.
$AGMB price target
AgomAb Therapeutics NV daily closes and this analyst's $35 target. Not advice.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. reiterated its rating for AgomAb Therapeutics with a buy rating and set a $35 price target. Earlier this year, on March 3, 2026, Leerink Partners, JP Morgan, and Morgan Stanley all initiated coverage with buy ratings, setting price targets at $36, $32, and $28, respectively. The consensus among analysts suggests a mean price target of $32, with three analysts offering opinions.
About AgomAb Therapeutics NV
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company based in Antwerp, Belgium. It develops innovative therapies for immunology and inflammatory diseases. The company's pipeline includes Ontunisertib, a treatment for Fibrostenosing Crohn's disease, and AGMB-447 for idiopathic pulmonary fibrosis. Founded in 2017, AgomAb is led by CEO Dr. Tim Knotnerus and employs 62 people.
Bottom Line
AgomAb Therapeutics NV continues to attract attention from analysts and investors alike, with HC Wainwright reaffirming its buy rating and a $35 target. The company's innovative approach in developing treatments for complex diseases makes it a noteworthy player in the biotechnology sector. As always, 13F filings and analyst ratings are backward-looking and may not represent the most current positions or opinions.
Related Filing Alerts
Source: HC Wainwright's rating change on $AGMB (Jun 22, 2026). Written by software, not financial advice. How we make alerts